Effect of Atorvastatin in Lipid Profile Changes and Inflammation Marker TNF-alpha on Diabetes Patient with Dyslipidemia

Wulan Panduwi Melasari, Suharjono Suharjono, Wiwid Samsulhadi

= http://dx.doi.org/10.20473/fmi.v57i1.26326
Abstract views = 366 times | downloads = 120 times

Abstract


Diabetes is one of the risk factors for cardiovascular disease (CVD). Diabetics patients have 2 to 4 times increased risk of cardiovascular disease compared with non-diabetics. TNF-alpha is a proinflammatory cytokine that can be used to determine the risk of atherosclerosis complications triggered by inflammation in diabetes. Statins are a class of HMG CoA reductase inhibitors that inhibit cholesterol biosynthesis and have pleioropic effects that inhibit the release of inflammatory cytokines like
TNF-alpha and stabilize atherosclerotic plaques. This study aims to determine the effect of atorvastatin 20 mg/day for 30 days in reducing the lipid profile and TNF-alpha inflammatory markers in patients with diabetes dyslipidemia. Diabetes patient with dyslipidemia who included the inclusion criteria in this observational prospective cohorts studies treated with atorvastatin for 30 days (n = 19). The efficacy of statin therapy was measured by lipid profiles (LDL, TG, HDL, and total cholesterol) and TNF-alpha. The results of the study showed that atorvastatin decreased 40.55% of LDL levels, 15.34% of TG levels, and 30.70% oftotal cholesterol levels which statistically significant (P <0.05). As for HDL, there is an increase of 6.06% but statistically non-significant (P >0.05). TNF-alpha levels increased by 11.30% which statistically non-significant (P >0.05). The use of atorvastatin 20 mg for 30 days gave reduction in LDL, TG, and total cholesterol and increased in HDL. Atorvastatin does not have a reducing effect on TNF-alpha. There was no correlation between lipid profile changes with TNF-alpha changes.

Keywords


Atorvastatin, lipid, TNF-α, diabetes, dyslipidemia

Full Text:

PDF

References


ADA. (2017). Standards of Medical Care in Diabetes, Diabetes Care Journal, volume 40, supplement 1, january 2017.

AHFS. (2011). AHFS Drug Information . Bathesda : American Society of Health System Pharmacists.

Belliaa, A., Rizzaa, S., Gallia, A., Fabianoa, R., Donadela, G., Lombardoa, M. F., et al. (2010). Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes . Atherosclerosis , 210, 199-201.

Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013). Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management . Drugs , 73, 327- 339.

Davignon, J. (2004). Beneficial Cardiovascular Pleiotropic Effects of Statins . Circulation , 109, III39–43 .

Deerochanawong, C., Buranakitjaroen, P., Piamsomboon, C. (2007). The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) Study in Thailand . Journal of the Medical Association of Thailand , 90 (1), 72-81.

Grossman, A., & Grossman, E. (2017). Blood pressure control in type 2 diabetic patients. Cardiovascular Diabetololy , 16, 1-15.

Lacy, C., Armstrong, L., Goldman, M., & Lance, L. (Eds.). (2016). Drug Information Handbook (24th ed.). New York: Lexicomp. 174-177.

Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013). Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Diabetes and vascular disease , 2436-2446.

PERKENI. (2015). Pengelolaan dan Pencegahan Diabetes mellitus Tipe 2 di Indonesia. 1-79.

Schachter, M. (2004). Chemical, pharmacokinetic and pharmacodinamic properties of statin : an update. Blackwell Publishing Fundamental & Clinical Pharmacology, Vol. 19, p.117-125.

Shaw, J. E., Sicree, R. A., Zimmet, P.Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 20130. Diabetes Research and Clinical Practice, vol 87, p.4-14.

Stancu, C. (2001). Statins: mechanism of action and effects . Journal of Cellular and Molecular Medicine , 5 (4), 378-387.

Triplitt, C., & Reasner, C. (2011). Diabetes mellitus. In e. a. Dipiro JT, Pharmacotheraphy : A Pathophysiology Approach. 8th Ed. New York: McGraw-Hill.

Tousoulis, D., Oikonomou, E., Economou, E. K., Crea, F., & Kaski, J. C. (2015). Inflammatory cytokines in atherosclerosis: current therapeutic approaches. European Heart Journal , 1-13.

Wu, L., & Parhofer, K. G. (2014). Diabetic dyslipidemia. Metabolism Clinical and Experimental , 63, 1468-1479.

Zhou, Q., & Liao, J. K. (2010). Pleiotropic effects of statins: basic research and clinical perspectives . Circulation , 818-826


Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Wulan Panduwi Melasari, Suharjono Suharjono, Wiwid Samsulhadi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed By

View My Stats

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.